Sanofi and CD&R join forces to grow Opella

Sanofi and CD&R announce a strategic collaboration to support the ambitions of Opella, a major player in consumer healthcare. The two companies have entered into exclusive negotiations for a 50% sale of Opella. Sanofi will remain a significant shareholder, while focusing on innovative medicines.

Opella, with its 11,000 employees, operates in 100 countries and manages iconic brands such as Allegra and Doliprane. Its valuation is approximately €16 billion. CD&R is set to support Opella with its expertise and network, with a view to continued global development.

The proposed transaction, expected to close in the second quarter of 2025, will strengthen Opella as an independent leader in consumer healthcare, while enabling Sanofi to pursue its biopharmaceutical and financial objectives for 2024.